Heart surgeon first to perform sutureless heart surgery in Washington state

Hassan Tehrani, MD, a Deaconess Hospital surgeon in Spokane, Washington, has become the first in the state to perform a heart valve replacement surgery using a less invasive, sutureless procedure, reports KomoNews.com.

The technique, which was approved by the U.S. Food and Drug Administration last August, treats stenosis, a condition in which the valve is so narrow it obstructs blood flow.

Though it’s been common practice to treat the condition with heart valves, they do wear out over time, bringing forth a need for a better solution.

In the sutureless procedure, Tehrani was able to place a rod where the aorta connects to the heart. Because the tools are smaller, the surgery is quicker.

To read more about the sutureless technique, follow the link below:

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.